# New Haven Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/new-haven-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Guilford, US
- Website: www.newhavenpharma.com
- Total disclosed funding: $18M
- Latest round: Series B (Oct 23, 2014)
- Investors on record: 4

## About

New Haven Pharmaceuticals Inc. specializes in developing innovative prescription drugs, utilizing established compounds to address unmet medical needs while ensuring patient safety and accessibility.New Haven Pharmaceuticals Inc. is focused on the development of prescription drugs utilizing well-established drugs and Generally Recognized As Safe (GRAS) active pharmaceutical ingredients. The company operates from Guilford, US. In October 2015, New Haven Pharmaceuticals secured USD 6.3 mn in VENTURE DEBT financing from Horizon Technology Finance Corporation, bringing its total amount raised to USD 11.79 mn. The company's endeavors indicate a strong commitment to advancing pharmaceutical solutions and enhancing patient care.New Haven Pharmaceuticals specializes in the development of prescription drugs that utilize well-established drugs and GRAS (Generally Recognized as Safe) active pharmaceutical ingredients. Their core product offerings focus on innovative drug formulations that leverage the safety profiles of known compounds, addressing various unmet medical needs across therapeutic areas. These products are designed for healthcare providers and patients seeking effective treatments with reduced regulatory barriers, ultimately enhancing patient care. The company aims to improve access to advanced medical therapies and targets markets within the United States and Europe, ensuring that its offerings reach a broad range of healthcare settings. By streamlining the drug development process, New Haven Pharmaceuticals positions itself as a leader in delivering safe, reliable, and life-enhancing pharmaceutical solutions.New Haven Pharmaceuticals generates revenue through a structured approach that includes partnerships with healthcare providers, pharmacies, and other stakeholders within the pharmaceutical supply chain. The company’s transactions typically involve direct sales of its innovative drug formulations to healthcare providers and retail pharmacies, facilitating access to its products for end-users. The revenue model encompasses various transaction structures, including B2B agreements with distributors and potential collaborations with healthcare organizations. Specific pricing plans and details regarding flagship products are aligned with the company's focus on ensuring competitive market positioning while maintaining high standards of safety and efficacy. This approach allows New Haven Pharmaceuticals to foster strong relationships with clients while meeting the demand for effective pharmaceutical solutions.New Haven Pharmaceuticals plans to leverage the recent USD 6.3 mn in VENTURE DEBT financing received in October 2015 to support its growth initiatives. The company is focused on designing and launching new products that meet the evolving needs of healthcare providers and patients. Additionally, New Haven Pharmaceuticals aims to expand into new markets, particularly within Europe, by 2025, ensuring that its innovative drug formulations are accessible to a broader audience. This strategic approach is expected to significantly enhance the company's market presence and impact within the pharmaceutical industry.

## Funding rounds

- Series B, Oct 23, 2014, $12M — Connecticut Innovations
- Series A, Oct 29, 2012, $6.6M — Advantage Capital, Connecticut Innovations, Kuzari Group, EJ Funds

## Investors

- Advantage Capital — Series A
- Connecticut Innovations (https://capitalatlas.ai/funds/connecticut-innovations) — Series A, Series B
- Kuzari Group (https://capitalatlas.ai/funds/kuzari-group) — Series A
- EJ Funds — Series A